PSCA-targeted CAR-T cells have demonstrated the capacity to delay tumor progression, whereas MUC1, particularly its glycosylated tumor-specific isoform (e.g., TnMUC1), offers a highly specific target for immunotherapy (71). The gene discussed is MUC1; the disease is neoplasm.